SCHEMBL4187828

SCHEMBL4187828

CC(C)(C)OC(=O)c1cccc(CCCCCCCCCCCC(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.56
MAPT P10636 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
CYP4F2 P78329 3/20 0.52
CYP4A11 Q02928 3/20 0.52
RXRA P19793 2/20 0.47
NR1H2 P55055 2/20 0.47
NR1H3 Q13133 1/20 0.47
TBXAS1 P24557 5/20 0.45
PPARG P37231 3/20 0.44
PPARA Q07869 3/20 0.44
HDAC3 O15379 1/20 0.44
MAPK1 P28482 1/20 0.44
ADRA1A P35348 1/20 0.44
HDAC4 P56524 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HDAC1 Q13547 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30873957 0.89 SLC7A5 (0.61) SLC7A5MAPTCYP4F2CYP4A11NR1H2
Adipic Acid SCHEMBL27893785 0.87 SLC7A5 (0.55) SLC7A5MAPTRXFP1RXRANR1H2
SCHEMBL4197208 0.87 CYP4F2 (0.56) SLC7A5MAPTCYP4F2CYP4A11PPARG
SCHEMBL4185656 0.84 SLC7A5 (0.47) SLC7A5CYP4F2CYP4A11HDAC1HDAC6
SCHEMBL14415229 0.83 CYP4A11 (0.68) SLC7A5CYP4F2CYP4A11NR1H2PPARG
SCHEMBL1743772 0.83 MAPT (0.54) MAPTRXFP1CYP4F2CYP4A11RXRA
SCHEMBL25961093 0.83 SLC7A5 (0.58) SLC7A5CYP4F2CYP4A11PPARGPPARA
SCHEMBL18744852 0.82 SLC7A5 (0.56) SLC7A5CYP4F2CYP4A11PPARGPPARA
SCHEMBL31688987 0.82 SLC7A5 (0.60) SLC7A5CYP4F2CYP4A11PPARGPPARA
SCHEMBL19078997 0.82 MAPT (0.45) SLC7A5MAPTRXFP1CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2024390-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-08-19 EP disclosed
US-8796205-B2 Insulin derivative NOVO NORDISK A/S (DK) 2014-08-05 US disclosed
US-20090105121-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
EP-2024390-A1 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2009-02-18 EP disclosed
WO-2007128815-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105121-A1 Insulin Derivative INSR, IAPP, GPR119 SLC7A5 357/4885MAPT 3955/4885RXFP1 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.